Cargando…
Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment
PURPOSE: For years, 5-fluorouracil (5-FU) has been the backbone of radiochemotherapy (RCT) of locally advanced rectal cancer. Its main target, thymidylate synthase (TS), is speculated to be an important biomarker for response prediction and long-term prognosis. In this study, we analyzed TS expressi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162628/ https://www.ncbi.nlm.nih.gov/pubmed/21347782 http://dx.doi.org/10.1245/s10434-011-1608-4 |
_version_ | 1782210841726156800 |
---|---|
author | Conradi, Lena-Christin Bleckmann, Annalen Schirmer, Markus Sprenger, Thilo Jo, Peter Homayounfar, Kia Wolff, Hendrik A. Rothe, Hilka Middel, Peter Becker, Heinz Ghadimi, Michael B. Beissbarth, Tim Liersch, Torsten |
author_facet | Conradi, Lena-Christin Bleckmann, Annalen Schirmer, Markus Sprenger, Thilo Jo, Peter Homayounfar, Kia Wolff, Hendrik A. Rothe, Hilka Middel, Peter Becker, Heinz Ghadimi, Michael B. Beissbarth, Tim Liersch, Torsten |
author_sort | Conradi, Lena-Christin |
collection | PubMed |
description | PURPOSE: For years, 5-fluorouracil (5-FU) has been the backbone of radiochemotherapy (RCT) of locally advanced rectal cancer. Its main target, thymidylate synthase (TS), is speculated to be an important biomarker for response prediction and long-term prognosis. In this study, we analyzed TS expression in the rectal cancer tissue of 208 patients to evaluate its predictive/prognostic potential. METHODS: All patients included were diagnosed with locally advanced adenocarcinoma of the rectum (UICC II and III) and were treated within randomized clinical trials of the German Rectal Cancer Study Group. Preoperative RCT (50.4 Gy and concomitant either 5-FU or 5-FU and oxaliplatin) was administered in 167 patients followed by surgical resection with total mesorectal excision (TME). Another 41 patients received postoperative RCT. TS levels and further clinicopathological parameters were assessed in univariate and multivariate analyses. Additionally, a TS gene polymorphism was analyzed with respect to the intratumoral protein levels. RESULTS: Low TS expression in pretreatment biopsies correlated with impaired patient survival (p = 0.015). Analysis of a 28-bp repeat revealed a correlation between the *3/*3 genotype and high TS expression in pretherapeutic biopsies. In this study, a correlation of TS expression and grade of RCT-induced tumor regression was not found. Histopathological examination confirmed a complete tumor remission in 16 patients (9.6%). Analyses of the resection specimen indicated an unfavorable prognosis for patients with low intratumoral TS expression in case of detected lymph node metastases (p = 0.04). CONCLUSIONS: TS can serve as a prognostic biomarker indicating an unfavorable prognosis for patients with low TS expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1245/s10434-011-1608-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3162628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-31626282011-09-26 Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment Conradi, Lena-Christin Bleckmann, Annalen Schirmer, Markus Sprenger, Thilo Jo, Peter Homayounfar, Kia Wolff, Hendrik A. Rothe, Hilka Middel, Peter Becker, Heinz Ghadimi, Michael B. Beissbarth, Tim Liersch, Torsten Ann Surg Oncol Gastrointestinal Oncology PURPOSE: For years, 5-fluorouracil (5-FU) has been the backbone of radiochemotherapy (RCT) of locally advanced rectal cancer. Its main target, thymidylate synthase (TS), is speculated to be an important biomarker for response prediction and long-term prognosis. In this study, we analyzed TS expression in the rectal cancer tissue of 208 patients to evaluate its predictive/prognostic potential. METHODS: All patients included were diagnosed with locally advanced adenocarcinoma of the rectum (UICC II and III) and were treated within randomized clinical trials of the German Rectal Cancer Study Group. Preoperative RCT (50.4 Gy and concomitant either 5-FU or 5-FU and oxaliplatin) was administered in 167 patients followed by surgical resection with total mesorectal excision (TME). Another 41 patients received postoperative RCT. TS levels and further clinicopathological parameters were assessed in univariate and multivariate analyses. Additionally, a TS gene polymorphism was analyzed with respect to the intratumoral protein levels. RESULTS: Low TS expression in pretreatment biopsies correlated with impaired patient survival (p = 0.015). Analysis of a 28-bp repeat revealed a correlation between the *3/*3 genotype and high TS expression in pretherapeutic biopsies. In this study, a correlation of TS expression and grade of RCT-induced tumor regression was not found. Histopathological examination confirmed a complete tumor remission in 16 patients (9.6%). Analyses of the resection specimen indicated an unfavorable prognosis for patients with low intratumoral TS expression in case of detected lymph node metastases (p = 0.04). CONCLUSIONS: TS can serve as a prognostic biomarker indicating an unfavorable prognosis for patients with low TS expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1245/s10434-011-1608-4) contains supplementary material, which is available to authorized users. Springer-Verlag 2011-02-23 2011 /pmc/articles/PMC3162628/ /pubmed/21347782 http://dx.doi.org/10.1245/s10434-011-1608-4 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Gastrointestinal Oncology Conradi, Lena-Christin Bleckmann, Annalen Schirmer, Markus Sprenger, Thilo Jo, Peter Homayounfar, Kia Wolff, Hendrik A. Rothe, Hilka Middel, Peter Becker, Heinz Ghadimi, Michael B. Beissbarth, Tim Liersch, Torsten Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment |
title | Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment |
title_full | Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment |
title_fullStr | Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment |
title_full_unstemmed | Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment |
title_short | Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment |
title_sort | thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment |
topic | Gastrointestinal Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162628/ https://www.ncbi.nlm.nih.gov/pubmed/21347782 http://dx.doi.org/10.1245/s10434-011-1608-4 |
work_keys_str_mv | AT conradilenachristin thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT bleckmannannalen thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT schirmermarkus thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT sprengerthilo thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT jopeter thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT homayounfarkia thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT wolffhendrika thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT rothehilka thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT middelpeter thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT beckerheinz thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT ghadimimichaelb thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT beissbarthtim thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment AT lierschtorsten thymidylatesynthaseasaprognosticbiomarkerforlocallyadvancedrectalcanceraftermultimodaltreatment |